Coinfection with<i>Strongyloides</i>and SARS-CoV-2: protocol for a systematic review
Abstract Rationale for the review COVID-19 treatment can worsen parasitic disease in patients with coinfection. Consequently, there is a need to investigate the infection with SARS-CoV-2 andStrongyloides. We aim to systematically review clinical and laboratory features of COVID-19 andStrongyloidescoinfection, to investigate possible interventions and outcomes in this pathology. Also, we aim to identify difficulties in managing the parasitic disease manifestations in this context and to emphasize research gaps requiring further attention.Methods We will search two electronic databases – LitCOVID, and WHO COVID-19 and will include studies on SARS-CoV-2 andStrongyloidescoinfection. We will adapt the WHO-UMC system for standardized case causality assessment to evaluate if using corticosteroids or other immunosuppressive drugs in COVID-19 patients determined acute strongyloidiasis manifestations.Expected results We will present the evidence in three distinct packages: study description, methodological quality assessment and data extracted. We will summarize the evidence and will draw conclusions as to the quality of the evidence..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
bioRxiv.org - (2023) vom: 02. Feb. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rosca, Elena C [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1101/2023.01.30.23285219 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI038572079 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI038572079 | ||
| 003 | DE-627 | ||
| 005 | 20230429101702.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230202s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2023.01.30.23285219 |2 doi | |
| 035 | |a (DE-627)XBI038572079 | ||
| 035 | |a (biorXiv)10.1101/2023.01.30.23285219 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rosca, Elena C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Coinfection with<i>Strongyloides</i>and SARS-CoV-2: protocol for a systematic review |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Rationale for the review COVID-19 treatment can worsen parasitic disease in patients with coinfection. Consequently, there is a need to investigate the infection with SARS-CoV-2 andStrongyloides. We aim to systematically review clinical and laboratory features of COVID-19 andStrongyloidescoinfection, to investigate possible interventions and outcomes in this pathology. Also, we aim to identify difficulties in managing the parasitic disease manifestations in this context and to emphasize research gaps requiring further attention.Methods We will search two electronic databases – LitCOVID, and WHO COVID-19 and will include studies on SARS-CoV-2 andStrongyloidescoinfection. We will adapt the WHO-UMC system for standardized case causality assessment to evaluate if using corticosteroids or other immunosuppressive drugs in COVID-19 patients determined acute strongyloidiasis manifestations.Expected results We will present the evidence in three distinct packages: study description, methodological quality assessment and data extracted. We will summarize the evidence and will draw conclusions as to the quality of the evidence. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Heneghan, Carl |e verfasserin |4 aut | |
| 700 | 1 | |a Spencer, Elizabeth A |e verfasserin |4 aut | |
| 700 | 1 | |a Plüddemann, Annette |e verfasserin |4 aut | |
| 700 | 1 | |a Maltoni, Susanna |e verfasserin |4 aut | |
| 700 | 1 | |a Gandini, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Onakpoya, Igho J |e verfasserin |4 aut | |
| 700 | 1 | |a Evans, David H |e verfasserin |4 aut | |
| 700 | 1 | |a Conly, John M |e verfasserin |4 aut | |
| 700 | 1 | |a Jefferson, Tom |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2023) vom: 02. Feb. |
| 773 | 1 | 8 | |g year:2023 |g day:02 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2023.01.30.23285219 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 02 |c 02 | ||